Navigation Links
UNC receives NIH grant to develop and test new drugs to block HIV infection
Date:7/18/2011

CHAPEL HILL, N.C. Scientists at the University of North Carolina at Chapel Hill schools of medicine and pharmacy have been awarded a $3 million federal grant to develop and test a new generation of treatments aimed at preventing sexual transmission of HIV to uninfected individuals. This remains the most common cause of HIV infection worldwide.

The new NIAID award is entitled Next Generation Pre-Exposure Prophylaxis, or PrEP. "This project combines the strengths of four outstanding investigators with highly complementary skills, at UNC and our industrial partner, Merck," said J. Victor Garcia-Martinez, PhD, the project's principal investigator and professor of medicine, and a member of UNC's Center for Infectious Diseases and Center for AIDS Research.

Project collaborators with Garcia-Martinez are Angela Kashuba, PharmD, associate professor, and Russell Mumper, PhD, McNeill Distinguished Professor, both in the UNC Eshelman School of Pharmacy, and Daria Hazuda, PhD, at Merck Research Laboratories. Merck will not receive federal funding from this award. "We will address issues of fundamental importance to the next generation of PrEP agents," Garcia-Martinez said.

The new grant from the National Institute of Allergy and Infectious Diseases (NIAID) follows the July 11 announcement of a $32 million award from the agency to UNC to lead scientists from eight other universities in the search for ways to purge hidden HIV from the immune systems of infected patients taking antiretroviral therapy.

"This new award serves as further testament to the outstanding environment for conducting state-of-the-art AIDS research at UNC and will strengthen the close ties between our programs in medicine and pharmacy," Garcia-Martinez said.

According to Garcia-Martinez, significant progress has been made in developing measures to prevent HIV infection, but recent results of clinical trials reveal that "the level of protection observed is suboptimal and that there is significant room for further improvement."

The UNC scientist also points out that most of the trials that are ongoing now involve drugs that are used for treatment, and to which there is drug-resistance in many parts of the world. "If you use for prevention the same drug you use for treatment, you may encounter situations where drug-resistant viruses might emerge. So we need to be ahead of the virus and to start working on HIV therapies that will be available for the next generation, which is the aim of this NIH initiative."

The new project will explore candidate drugs, experimental compounds, not yet tested in people. Preclinical experiments will be conducted in humanized BLT mice. The "BLT" name is derived from the fact that these designer mice are created one at a time by introducing human bone marrow, liver and thymus tissues into animals without an immune system of their own.

Humanized BLT mice have a fully functioning human immune system and can be infected with HIV in the same manner as humans. The laboratory of Garcia-Martinez has pioneered the development of this humanized mouse model. "Prevention of sexual transmission of HIV is urgently needed," he said.


'/>"/>

Contact: Les Lang
llang@med.unc.edu
919-966-9366
University of North Carolina School of Medicine
Source:Eurekalert  

Related medicine news :

1. UCSF receives $112 million to help translate science into cures
2. Wayne State University engineering student receives American Tinnitus Association award
3. Allina receives NIH grant to study real world usage of integrative therapies
4. Brookhaven Labs Joanna Fowler receives Distinguished Women in Chemistry Award
5. UH Cancer Center receives $3.58 million gift for mesothelioma research
6. UC Riverside botanist receives high honor from Howard Hughes Medical Institute
7. Illinois professor John A. Rogers receives $500,000 Lemelson-MIT Prize
8. Penn State receives $27.3 million NIH grant
9. University of Houston researcher receives grant to study water pollutants
10. Rhode Island Hospital fellow receives funding to support research in myocardial perfusion
11. Pioneering stem cell bandage receives approval for clinical trial
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
UNC receives NIH grant to develop and test new drugs to block HIV infection
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American ... Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. ... including advance care planning, healthcare costs and patient and family engagement. , AIR ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... As a ... Magna Cum Laude and his M.D from the David Geffen School of Medicine at ... returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars ...
(Date:6/24/2016)... ... 24, 2016 , ... Those who have experienced traumatic events may suffer from ... avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid this ... coping following a traumatic event. , Trauma sufferers tend to feel a range of ...
(Date:6/24/2016)... San Francisco, CA (PRWEB) , ... June 24, ... ... at CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has ... , self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty ... Barry M. Weintraub as a prominent plastic surgeon and the network’s newest partner. ... and the most handsome men, look naturally attractive. Plastic surgery should be invisible.” ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
(Date:6/23/2016)... the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in Bogota. Colombia ... ... Sandra ... ... Astellas is a pharmaceutical company ...
(Date:6/23/2016)... FRANKLIN, Tenn. , June 23, 2016 ... for automating, integrating and transforming the patient ... launch of several innovative new products and ... depth of its revenue cycle offerings. These ... establish more efficient workflows, remain compliant in ...
Breaking Medicine Technology: